ANNOUNCES PROSPECTIVE RANDOMIZED CONTROL TRIAL AT DUKE UNIVERSITY MEDICAL CENTER TO GUIDE VOLUME TREATMENT IN HEART FAILURE PATIENTS
Commences Using the BVA-100® Diagnostic Blood Test
YORK, July 16, 2020 — Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and
biotechnology operations focused on blood volume measurement, today announced the initiation of a prospective randomized control
trial (RTC) utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology to guide volume treatment in
heart failure patients. Duke University Medical Center has begun enrolling patients under the leadership of Marat Fudim, MD, MHS
and G. Michael Felker, MD, MHS.
study builds upon existing evidence showing that Daxor’s direct blood volume measurement has significant clinical and economic
benefits for patients and hospitals and is part of Daxor’s portfolio of active research partnerships further driving BVA
adoption at major hospital centers,” said Michael Feldschuh, CEO and President of Daxor Corporation. “The BVA blood
test provides clinicians with precise intravascular volume measures to guide individualized fluid therapy to achieve better outcomes.
The BVA test is reimbursed by both Medicare and most private insurers so hospitals can realize significant financial gains along
with improvements in their quality metrics. We are excited to partner with Duke University Medical Center, and Dr. Fudim, who
has previously published on the clinical utility of BVA in the assessment of heart failure and hypertension.”
Fudim commented, “Volume management is key to the successful management of heart failure and we are excited to study the
utility of BVA in the setting of acute heart failure.”
study follows Daxor’s recent announcement of the initiation of a first-of-its-kind prospective multicenter BVA trial in
hospitalized COVID-19 patients. Both trials highlight that volume derangements are common in a diverse set of medical conditions
and are designed to add to the scientific body of evidence which has demonstrated the impact of Daxor’s BVA test on improved
patient care and outcomes.
BVA test has been associated with a reduction in heart failure 30-day mortality by 82%, 30-day readmissions by 56%, and 1-year
mortality by 86% in a peer-reviewed study published in December 2018 in the Journal of the American College of Cardiology -
Heart Failure titled “Heart Failure Outcomes With Volume Guided Management.”
Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement.
We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide
safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology
has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions, including heart
failure and critical care, by informing treatment strategies, resulting in significantly improved patient outcomes. Our mission
is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for
patients. For more information, please visit our website at Daxor.com.
statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution
channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future
events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated
with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect
to product development and commercialization efforts, our ability to increase market and physician acceptance of our products,
potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate
acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional
other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when
made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
Managing Partner, CORE IR